BMY
BRISTOL MYERS SQUIBB CO
- PER (TTM)
- 15.73
- PER (Forward)
- 9.14
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 5.71
- 시가총액
- 114.68B
- 배당수익률
- 449.00%
- 베타
- 0.26
- 1개월 수익률
- -5.57%
- 3개월 수익률
- -8.47%
- 6개월 수익률
- 23.54%
- 1년 수익률
- 23.83%
- 2년 수익률
- -
- 5일 평균거래량
- 10331160
- 60일 평균거래량
- 12052410
- 1년 평균거래량
- 13879832
- 5d/60d 거래량 비율
- 0.86×
- 60d/1y 거래량 비율
- 0.87×
- 변동성(60일, 연환산)
- 24.53%
- BB 스퀴즈 스코어
- 0.66
- SMA50 비율
- 0.96
- SMA200 비율
- 1.09
- RSI (14)
- 40
- 20일 수렴도
- 0.02
- 52주 최고
- 61.73
- 52주 최저
- 41.67
- 고점 대비
- -9.03%
- 저점 대비
- 34.76%
펀더멘털 갱신: 2026-05-10T08:02:45+00:00 · 시세 갱신: 2026-05-10T06:13:39+00:00
회사 정보
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.